By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Small Interference RNAs (siRNAs). According to news reporting from Hershey, Pennsylvania, by NewsRx journalists, research stated, "CD47 is a 'self marker' that is usually overexpressed on the surface of cancer cells to enable them to escape immunosurveillance. Recognition of CD47 by its receptor, signal regulatory protein alpha (SIRP alpha), which is expressed in the macrophages, inhibits phagocytic destruction of cancer cells by the macrophages."
The news correspondents obtained a quote from the research from Pennsylvania State University, "In this study, we have first shown that clinical isolates of human melanoma significantly upregulate CD47, possibly as a mechanism to defend themselves against the macrophages. We then exploited RNA interference (RNAi) technology to test the hypothesis that knocking down CD47 in the tumor cells will render them targets for macrophage destruction; hence, creating a novel anti-cancer therapy. Anti-CD47 siRNA was encapsulated in a liposome-protamine-hyaluronic acid (LPH) nanoparticle (NP) formulation to address the challenge of targeted delivery of siRNA-based therapeutics in vivo. Efficient silencing of CD47 in tumor tissues with systemic administration of LPH(CD47) also significantly inhibited the growth of melanoma tumors. In a lung metastasis model, LPH(CD47) efficiently inhibited lung metastasis to about 27% of the untreated control. Moreover, no hematopoietic toxicity was observed in the animals that received multiple doses of LPH(CD47)."
According to the news reporters, the research concluded: "Our findings indicate CD47 as a potential prognostic marker for melanoma development as well as a target for therapeutic intervention with RNAi-based nanomedicines."
For more information on this research see: Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis. Molecular Therapy, 2013;21(10):1919-1929. Molecular Therapy can be contacted at: Nature Publishing Group, 75 Varick St, 9TH Flr, New York, NY 10013-1917, USA. (Elsevier - www.elsevier.com; Molecular Therapy - www.elsevier.com/wps/product/cws_home/622922)
Our news journalists report that additional information may be obtained by contacting Y.H. Wang, Pennsylvania State University, Coll Med, Dept. of Surg, Hershey, PA, United States. Additional authors for this research include Z.H. Xu, S.T. Guo, L. Zhang, A. Sharma, G.P. Robertson and L. Huang (see also Small Interference RNAs (siRNAs)).
Keywords for this news article include: Cancer, Hershey, Genetics, Oncology, Melanomas, Immunology, Macrophages, Pennsylvania, Therapeutics, United States, Myeloid Cells, Connective Tissue Cells, North and Central America, Mononuclear Phagocyte System, Small Interference RNAs (siRNAs)
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC